Literature DB >> 30297113

The expected cumulative incidence of live birth for patients starting IVF treatment at age 41 years or older.

Oshrit Lebovitz1, Jigal Haas2, Kaitlyn E James3, Daniel S Seidman2, Raoul Orvieto2, Ariel Hourvitz2.   

Abstract

RESEARCH QUESTION: What is the cumulative incidence of live birth (CILB) for high-order consecutive IVF cycles, and which factors are associated with live birth in women aged ≥41 years using autologous oocytes?
DESIGN: A retrospective cohort study including 146 patients aged 41 years to <44 years who started their first IVF cycle attempt using autologous oocytes, between January 2006 and December 2013.
RESULTS: After 13 IVF cycles, CILB reached up to 33.6%. After six IVF cycles, 42 (28.8%) women delivered a live infant (85.7% of the total live birth). Mean live birth rate per cycle declined with age at the initial cycle (8% at 41 years; 5.8% at 42 years; and 4.1% at 43 years). Multivariable modified Poisson regression models identified patient's age (RR for 41 years versus 43 years: 0.47; 95% CI 0.25 to 0.87; P = 0.01), smoking status (RR 0.21; 95% CI 0.05 to 0.08; P = 0.02), and mean number of fertilized oocytes (RR 1.23; 95% CI 1.08 to 1.39; P < 0.01) as factors significantly associated with the probability of a live birth.
CONCLUSIONS: Multiple repeat IVF cycles in women aged 41-44 years offers a reasonable long-term success rate. After six cycles of treatment, about 29% of women of advanced reproductive age using autologous oocytes expected to achieve a live birth. This information might assist in fertility counselling and managing patients' expectations by adjusting the appropriate treatment strategy and number of IVF cycle attempts, especially in countries in which egg donation is prohibited or when multiple repeated IVF cycles attempts are financially affordable.
Copyright © 2018 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Advanced maternal age; Cumulative live birth rate; IVF

Mesh:

Year:  2018        PMID: 30297113     DOI: 10.1016/j.rbmo.2018.08.014

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  5 in total

1.  Clinical outcome of planned oocyte cryopreservation at advanced age.

Authors:  Avi Tsafrir; Ido Ben-Ami; Talia Eldar-Geva; Michael Gal; Nava Dekel; Hadassah Levi; Oshrat Schonberger; Naama Srebnik; Amir Weintraub; Doron Goldberg; Jordana Hyman
Journal:  J Assist Reprod Genet       Date:  2022-10-20       Impact factor: 3.357

2.  Future fertility of patients with zero oocytes yield in their first IVF cycle attempt.

Authors:  Raoul Orvieto; Jacob Farhi; Ravit Nahum; Shani Basch; Jigal Haas; Adva Aizer
Journal:  PLoS One       Date:  2021-02-16       Impact factor: 3.240

3.  Biphasic (5-2%) oxygen concentration strategy significantly improves the usable blastocyst and cumulative live birth rates in in vitro fertilization.

Authors:  Sophie Brouillet; Chloé Baron; Fatima Barry; Aneta Andreeva; Delphine Haouzi; Anna Gala; Alice Ferrières-Hoa; Vanessa Loup; Tal Anahory; Noémie Ranisavljevic; Laura Gaspari; Samir Hamamah
Journal:  Sci Rep       Date:  2021-11-17       Impact factor: 4.379

Review 4.  Mining of variables from embryo morphokinetics, blastocyst's morphology and patient parameters: an approach to predict the live birth in the assisted reproduction service.

Authors:  Dóris Spinosa Chéles; Eloiza Adriane Dal Molin; José Celso Rocha; Marcelo Fábio Gouveia Nogueira
Journal:  JBRA Assist Reprod       Date:  2020-10-06

5.  Optimising Follicular Development, Pituitary Suppression, Triggering and Luteal Phase Support During Assisted Reproductive Technology: A Delphi Consensus.

Authors:  Raoul Orvieto; Christos A Venetis; Human M Fatemi; Thomas D'Hooghe; Robert Fischer; Yulia Koloda; Marcos Horton; Michael Grynberg; Salvatore Longobardi; Sandro C Esteves; Sesh K Sunkara; Yuan Li; Carlo Alviggi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-10       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.